Literature DB >> 18779048

Tuberculosis in Africa: learning from pathogenesis for biomarker identification.

Stefan H E Kaufmann1, Shreemanta K Parida.   

Abstract

In Africa, more than 4 million people suffer from active tuberculosis (TB) resulting in an estimated 650,000 deaths every year. The etiologic agent of TB, Mycobacterium tuberculosis, survives in resting macrophages, which control the pathogen after activation by specific T lymphocytes. Here, we describe the basic mechanisms underlying the host response to TB with an emphasis on immunity and discuss diagnostics, drugs, and vaccines for TB. Moreover, we outline our attempts to develop biomarkers, which could help the monitoring of TB clinical trials, provide the basis for new diagnostics, and allow prognosis of outcome of infection and of drug treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779048     DOI: 10.1016/j.chom.2008.08.002

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  30 in total

1.  True facets of TB diagnosis in 2012: Hypes and realities.

Authors:  S K Parida
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-12-11

2.  Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis.

Authors:  Claire Lastrucci; Alan Bénard; Luciana Balboa; Karine Pingris; Shanti Souriant; Renaud Poincloux; Talal Al Saati; Voahangy Rasolofo; Pablo González-Montaner; Sandra Inwentarz; Eduardo Jose Moraña; Ivanela Kondova; Frank A W Verreck; Maria del Carmen Sasiain; Olivier Neyrolles; Isabelle Maridonneau-Parini; Geanncarlo Lugo-Villarino; Céline Cougoule
Journal:  Cell Res       Date:  2015-10-20       Impact factor: 25.617

Review 3.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

4.  Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis.

Authors:  Desta Kassa; Leonie Ran; Wudneh Geberemeskel; Mekashaw Tebeje; Amelewerk Alemu; Alemayehu Selase; Belete Tegbaru; Kees L M C Franken; Annemieke H Friggen; Krista E van Meijgaarden; Tom H M Ottenhoff; Dawit Wolday; Tsehaynesh Messele; Debbie van Baarle
Journal:  Clin Vaccine Immunol       Date:  2012-09-26

5.  Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition.

Authors:  Rebecca Axelsson-Robertson; Raija K Ahmed; Frank F Weichold; Marthie M Ehlers; Marleen M Kock; Donata Sizemore; Jerry Sadoff; Markus Maeurer
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

Review 6.  New diagnostic methods for tuberculosis.

Authors:  Melissa R Nyendak; Deborah A Lewinsohn; David M Lewinsohn
Journal:  Curr Opin Infect Dis       Date:  2009-04       Impact factor: 4.915

7.  Exploratory study on plasma immunomodulator and antibody profiles in tuberculosis patients.

Authors:  Resmi Ravindran; Viswanathan V Krishnan; Azra Khanum; Paul A Luciw; Imran H Khan
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

8.  Structural analysis reveals DNA binding properties of Rv2827c, a hypothetical protein from Mycobacterium tuberculosis.

Authors:  Robert Janowski; Santosh Panjikar; Ali Nasser Eddine; Stefan H E Kaufmann; Manfred S Weiss
Journal:  J Struct Funct Genomics       Date:  2009-01-31

9.  Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.

Authors:  Steven G Smith; Simone A Joosten; Virginie Verscheure; Ansar A Pathan; Helen McShane; Tom H M Ottenhoff; Hazel M Dockrell; Françoise Mascart
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

10.  Complex cytokine profiles induced by BCG vaccination in UK infants.

Authors:  Maeve K Lalor; Steven G Smith; Sian Floyd; Patricia Gorak-Stolinska; Rosemary E Weir; Rose Blitz; Keith Branson; Paul E Fine; Hazel M Dockrell
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.